Layered uncertainties make this case an unusually difficult case in which to predict the outcome
On April 15, the Supreme Court will hear oral argument in Association for Molecular Pathology v. Myriad Genetics, a case that could answer the question, “Under what conditions, if any, are isolated human genes patentable?” Kevin Emerson Collins, JD, patent law expert and professor of law at Washington University in St. Louis, believes that layered uncertainties make this case an unusually difficult case in which to predict the outcome.
During the early 1990s, Myriad Genetics made important scientific discoveries related to mutations in the BRCA 1 and BRCA 2 genes, which are biomarkers for increased risk of breast and ovarian cancer. Based on this work, Myriad sought, and obtained, patent protection for “isolated” DNA molecules that embody these sequences.
The Supreme Court’s opinion in Myriad will determine whether Myriad’s gene patents are valid or, alternatively, whether they were improperly issued from the beginning.
“The legal controversy centers on patent law’s ‘products of nature’ doctrine—a doctrine that prevents the patenting of newly made products that do not display a ‘marked difference’ from naturally occurring products,” Collins says.
“A perfectly circular section cut out of a leaf of a newly discovered plant may be technically new at the time that it is first made – and it may be socially useful if the leaf contains chemicals that are natural wound healers, but it’s likely an unpatentable product of nature because there is no marked difference between the newly created product and the naturally occurring product.
“Importantly, the Myriad gene patents only encompass DNA molecules in an ‘isolated’ state, separate from the remainder of the chromosome in which they exist in a human body, and they thus describe molecules that were technically new when Myriad first made them.”
The question before the Court is whether the structural and functional differences between naturally occurring DNA molecules and DNA molecules in an isolated state is sufficiently significant to constitute a “marked difference” and to sanction the patenting of the isolated DNAs.
Behind the legal controversy is an economic controversy that may (or may not) influence the Supreme Court’s pronouncement on the products of nature doctrine. “The social costs of the exclusive rights to inventions granted by patents are normally justified by the incentives that patents provide for self-interested entities to invest in research and development and generate the socially valuable inventions,” Collins says.
However, under some circumstances, there are legitimate concerns that the incentive-based benefits of patents may not outweigh these costs.
“One function of the products of nature doctrine is to ensure that the basic tools of scientific and technological work are not constrained by claims of patent rights and remain free for all to use as inputs into future research,” says Collins.
“To the extent that isolated genes are essential technological and scientific building blocks, the costs of Myriad’s gene patents in the form of slower innovation in the future may be so great that they will outweigh the benefits of the patent-induced incentives that speed up the creation of the isolated genes themselves.”
The verdict
The Latest Bing News on:
Are human genes patentable
- How Quantum Computers Could Illuminate the Full Range of Human Genetic Diversityon April 26, 2024 at 10:26 am
Pangenomes that incorporate many people’s DNA could capture the breadth of human genetic diversity, and quantum computers may be a key enabler.
- OpenCRISPR-1: World’s first open-source AI scissor edits human geneson April 25, 2024 at 6:14 am
This launch marks the successful precision editing of the human genome using customizable gene editors crafted entirely through AI.
- A genetic patch corrects a rare syndrome in human brain organoid grafted into a raton April 24, 2024 at 9:51 am
The team led by Sergiu Pasca, from Stanford University, wants to test this promising strategy in children with Timothy Syndrome, which is associated with autism and epilepsy ...
- AI-designed gene editing tools successfully modify human DNAon April 24, 2024 at 5:51 am
Medically, AI is helping us with everything from identifying abnormal heart rhythms before they happen to spotting skin cancer. But do we really need it to get involved with our genome? Protein-design ...
- Profluent Successfully Edits Human Genome with OpenCRISPR-1, the World’s First AI-Created and Open-Source Gene Editoron April 22, 2024 at 9:30 am
With this launch, Profluent demonstrates the first successful precision editing of the human genome with customizable gene editors designed from scratch with AI. OpenCRISPR-1 is an AI-created gene ...
- The scramble to patent human geneson April 14, 2024 at 6:35 pm
Most biologists know that the human genome, with its 100,000 or so genes, is expected to be fully ... appear to be patentable, at least in the United States, where the US Patent and Trademark ...
- How Many Genes Do Humans Have?on March 31, 2024 at 5:00 pm
Protein-coding versus noncoding genes When deciding the number of genes in the human genome, Human Genome Project researchers initially counted protein-coding genes—regions of chromosomal DNA that are ...
- Second International Summit on Human Gene Editingon March 9, 2024 at 1:49 pm
The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...
- Revealing the Genes that Shape the Human Brainon August 1, 2022 at 9:50 am
Neurologist Christopher Walsh discovered genes that direct cerebral cortex development. We asked him what they reveal about intelligence, psychiatric disorders, and the nature of being human This ...
- Cracking the Code of Lifeon October 31, 2018 at 12:01 am
When a patent is submitted to the government, the company must prove that the item to be patented is original and patentable ... patenting a gene that already exists in the human body?
The Latest Google Headlines on:
Are human genes patentable
[google_news title=”” keyword=”Are human genes patentable” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
[/vc_column_text]
The Latest Bing News on:
Gene patents
- Pfizer Gets FDA Approval For Rare Inherited Bleeding Disorder Gene Therapyon April 26, 2024 at 1:39 pm
In announcing its approval on Friday, the Food and Drug Administration said it had approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first gene therapy to ...
- FDA approves Pfizer’s gene therapy Beqvez for adults with hemophilia Bon April 26, 2024 at 8:46 am
Developed by US pharma giant Pfizer (NYSE: PFE), Beqvez is authorized for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have ...
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024on April 25, 2024 at 1:02 pm
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of ...
- Meeting the cell and gene therapy scale-up challengeon April 25, 2024 at 9:00 am
One of the pivotal challenges in the development and commercialisation of cell and gene therapies (CGT) lies in scaling up production. This challenge is particularly pronounced as companies transition ...
- Gene Therapy For Ocular Rare Disease Pipeline Insight Report 2024on April 25, 2024 at 1:06 am
The "Gene Therapy For Ocular Rare Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights of present clinical ...
- HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECGon April 24, 2024 at 8:00 am
Today, measures of diastolic function of the heart need to be assessed in a specialist cardiology environment, typically using echocardiography-based imaging. The ability to assess cardiac diastolic ...
- AstraZeneca and Merck's Lynparza set to 'dominate' PARP marketon April 24, 2024 at 5:23 am
AstraZeneca and Merck & Co. were the first to grab an FDA approval for their PARP inhibitor Lynparza, and, despite growing competition, the drug is set to remain top dog in the PARP space. | ...
- Moderna Investors Should Beware Patent-Dispute Fallouton April 23, 2024 at 11:40 am
Moderna's stock soared on positive cancer vaccine trial results, but legal troubles loom as a patent dispute threatens massive damages. Read my analysis here.
- USDA Grants Amfora Exemption for Its Patented, Gene-Edited, Ultra-High Protein Soy, Accelerating Path to Marketon April 23, 2024 at 5:16 am
The U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) has granted Amfora, Inc. an exemption for its gene-edited, ultra-high protein soybeans. The exemption is a ...
- Iovance Biotherapeutics gets grant for gene-edited til composition with enhanced IFN secretionon April 22, 2024 at 5:20 am
Discover the groundbreaking patent by Iovance Biotherapeutics Inc for gene-edited TILs, enhancing efficacy and reducing costs in cancer immunotherapy.
The Latest Google Headlines on:
Gene patents
[google_news title=”” keyword=”gene patents” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]